Bruker Corporation
NASDAQ:BRKRMedical - Devices
-$1.07 today
- Market cap
- $9.66B
- Beta
- 1.30
- P/E (TTM)
- -718.1
- EPS (TTM)
- -$0.08
- Dividend yield
- 0.37%
Volume 1.73M
Average 2.41M
BRKR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Bruker CorporationNASDAQ: BRKR
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA declines year over year
Q2 FY2026 EBITDA of $17.3M fell 76.1% year over year, behind the -38.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 80.5% from the prior quarter. Over 3 fiscal years it compounded at -16.4% a year.
Context
- EBITDA amounted to 8.8% of revenue in FY2025, down 4.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $657.13M (+117.2%) for the fiscal year ending Dec 2026, a step up from the -31.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $17.3M-80.5% QoQ
- Last fiscal yearDec 2025
- $302.6M-31.0% YoY
- LTMJun 2026
- $247.7M-38.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -76.1% | +3177.6% | +3253.7 pp |
| 1 year | -31.0% | +117.2% | +148.2 pp |
| 3-year CAGR | -16.4% | +36.5% | +53.0 pp |
| 5-year CAGR | +24.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 302.6M USD
- Year-over-year change
- -31.0%
- 4-year CAGR
- -11.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 302.6M | -31.0% |
| FY2024 | 2024-12-31 | 438.6M | -35.1% |
| FY2023 | 2023-12-31 | 675.5M | +30.2% |
| FY2022 | 2022-12-31 | 518.7M | +4.4% |
| FY2021 | 2021-12-31 | 497M | — |
EBITDA vs competitors
How BRKR compares with its peers on the latest reported figures
- BRKR's LTM Jun 2026 EBITDA of $247.7M is the 10th highest of the 11 companies compared; the peer median is $858.88M.
- Its year-over-year change of -38.6% is the lowest of 11, against a peer median of +1.2%.
- EBITDA amounts to 7.1% of revenue for BRKR, versus a peer median of 27.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.24B | -0.8% | -1.3% | 23.7% | |
| LTM Sep 2026 | $7.09B | +3.2% | -9.9% | 27.7% | |
| LTM Jul 2026 | $2.04B | +13.2% | -1.2% | 27.6% | |
| LTM Jun 2026 | $1.31B | +7.1% | +0.1% | 31.6% | |
| LTM Jul 2026 | $950.77M | -10.1% | -0.2% | 20.5% | |
| LTM Jul 2026 | $767M | -6.7% | -13.5% | 26.3% | |
| LTM Jun 2026 | $703.39M | -1.6% | -2.7% | 33.5% | |
| LTM Jun 2026 | $514.7M | -22.7% | — | 19.9% | |
| LTM Sep 2026 | $328.77M | +48.3% | -9.1% | 26.8% | |
| LTM Jun 2026 | $247.7M | -38.6% | -16.4% | 7.1% | |
| LTM Mar 2026 | -$106.6M | +54.1% | — | 66.6% | |
| Peer median (excluding BRKR) | $858.88M | +1.2% | -2.0% | 27.2% | |
Competitors are the stored peer set for BRKR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.42B | 2.53B | 2.96B | 3.37B | 3.44B |
| Cost of Revenue | 1.21B | 1.23B | 1.45B | 1.72B | 1.86B |
| Gross Profit | 1.21B | 1.31B | 1.51B | 1.65B | 1.58B |
| Gross Margin | 50.0% | 51.6% | 51.0% | 49.0% | 45.9% |
| Research & Development | 220.8M | 235.9M | 294.8M | 376.5M | 395.2M |
| Selling, General & Admin | 562.3M | 607.4M | 729.4M | 893.8M | 946.5M |
| Operating Expenses | 796.3M | 873M | 1.08B | 1.4B | 1.34B |
| Depreciation & Amortization | 89.1M | 88.7M | 114.9M | 183.8M | 220.3M |
| EBITDA | 497M | 518.7M | 675.5M | 438.6M | 302.6M |
| EBITDA Margin | 20.6% | 20.5% | 22.8% | 13.0% | 8.8% |
| Operating Income | 413.3M | 432.7M | 436.9M | 253.1M | 236M |
| Operating Margin | 17.1% | 17.1% | 14.7% | 7.5% | 6.9% |
| Interest Income | 900K | 2.8M | 7.5M | 9.3M | 14.8M |
| Interest Expense | 14.3M | 16.1M | 16.4M | 47.9M | 60.3M |
| Other Income / Expenses | (19.7M) | (17.8M) | 109.3M | (47.9M) | (215M) |
| Income Before Tax | 393.6M | 414.9M | 546.2M | 205.2M | 21M |
| Pre-Tax Margin | 16.3% | 16.4% | 18.4% | 6.1% | 0.6% |
| Income Tax Expense | 113M | 116.4M | 117.7M | 91.4M | 29.3M |
| Net Income | 277.1M | 296.6M | 427.2M | 113.1M | (8.6M) |
| Net Margin | 11.5% | 11.7% | 14.4% | 3.4% | -0.3% |
| EPS (Basic) | 1.83 | 2.00 | 2.92 | 0.76 | (0.15) |
| EPS (Diluted) | 1.81 | 1.99 | 2.90 | 0.76 | (0.15) |
| Weighted Avg Shares | 151.4M | 148.6M | 146.4M | 149M | 151.8M |
| Weighted Avg Shares (Diluted) | 152.9M | 149.4M | 147.2M | 149.5M | 151.8M |
Bruker Corporation
NASDAQ:BRKR
Intrinsic Alpha fair value
Locked
Current Price
$63.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.